Company Description

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast stem cell driven diseases in the United States.

The company’s lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factors from binding to and signaling through the CD117 receptor on mast and stem cells.

It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma.

Jasper Therapeutics, Inc. was founded in 2018 and is headquartered in Redwood City, California.

Jasper Therapeutics, Inc.

Country	United States
Founded	2018
Industry	Biotechnology
Sector	Healthcare
Employees	22
CEO	Jeetinder Mahal

Contact Details

Address: 2200 Bridge Pkwy, Suite 102 Redwood City, California 94065 United States
Phone	650 549 1400
Website	jaspertx.com

Stock Details

Ticker Symbol	JSPR
Exchange	NASDAQ
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	1788028
CUSIP Number	471871202
ISIN Number	US4718712023
Employer ID	84-2984849
SIC Code	2836

Key Executives

Name	Position
Thomas G. Wiggans	Executive Chairman
Dr. Judith Anne Shizuru M.D., Ph.D.	Co-Founder, Member of Scientific Advisory Board and Director

Latest SEC Filings

Date	Type	Title
Aug 3, 2026	8-K	Current Report
Jul 31, 2026	8-K	Current Report
Jul 20, 2026	SCHEDULE 13D/A	Filing
Jul 17, 2026	8-K	Current Report
Jul 16, 2026	8-K	Current Report
Jul 10, 2026	SCHEDULE 13G/A	Filing
Jun 15, 2026	ARS	Filing
Jun 15, 2026	DEFA14A	Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Jun 15, 2026	DEF 14A	Other definitive proxy statements
Jun 9, 2026	8-K	Current Report

View All SEC Filings